# YS BIOPHARMA CO LTD (LSB)

> Institutional ownership reported to the SEC as of Q3 2024, from Form 13F filings. Source: https://holderbook.com/stocks/LSB/

- Reporting holders: 7
- Reported value: $2.2M
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [FMR LLC](https://holderbook.com/funds/315066-fmr-llc/) | $802.7K | 1,165,071 | 0.0% | 7 |
| [HHLR ADVISORS, LTD.](https://holderbook.com/funds/1762304-hhlr-advisors-ltd/) | $512.7K | 751,790 | 0.0% | 7 |
| [FIL Ltd](https://holderbook.com/funds/318989-fil-ltd/) | $424.1K | 615,475 | 0.0% | 7 |
| [SUPERSTRING CAPITAL MANAGEMENT LP](https://holderbook.com/funds/1931118-superstring-capital-management-lp/) | $212.2K | 307,920 | 0.2% | 4 |
| [BARCLAYS PLC](https://holderbook.com/funds/312069-barclays-plc/) | $168.8K | 247,575 | 0.0% | 2 |
| [BANK OF MONTREAL /CAN/](https://holderbook.com/funds/927971-bank-of-montreal-can/) | $75.5K | 93,808 | 0.0% | 3 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $33.7K | 49,418 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2024 | 7 | $2.2M |
| Q2 2024 | 11 | $3.3M |
| Q1 2024 | 9 | $3.8M |
| Q4 2023 | 10 | $4.9M |
| Q3 2023 | 11 | $8.9M |
| Q2 2023 | 14 | $13.2M |
| Q1 2023 | 13 | $22.3M |